Skip to main content
logo
NGeneBio Co., Ltd. (KOSDAQ:354200)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,275.00
+278.00 (13.92%)
At close: Aug 11, 2026

NGeneBio Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
31,20021,2405,6114,35111,0187,163
Revenue Growth
363.66%278.54%28.96%-60.51%53.81%-
Gross Profit
4,2423,7762,049-153.654,1282,390
Operating Income
-7,800-8,276-12,592-13,425-8,599-8,732
Net Income
-7,000-5,542-12,976-12,769-9,785-8,431
Earnings Per Share
-873.48-739.37-2745.00-3021.00-2352.64-2046.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
6,4135,6757,49622,42734,91824,307
Total Debt
32,68133,2499,01911,44411,4567,207
Net Cash (Debt)
-26,267-27,574-1,52310,98323,46217,100
Net Cash Growth
----53.19%37.20%-
Net Cash Per Share
-3277.86-3678.51-322.182597.565640.724147.91

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-5,193-8,482-12,431-9,167-7,820-7,523
Capital Expenditures
-26,628-25,852-135.37-386.37-1,029-3,023
Free Cash Flow
-31,821-34,334-12,566-9,553-8,849-10,546
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
13.60%17.78%36.52%-3.53%37.47%33.36%
Operating Margin
-25.00%-38.96%-224.42%-308.56%-78.05%-121.90%
Pretax Margin
-20.24%-20.33%-196.91%-302.82%-89.31%-117.70%
Profit Margin
-22.43%-26.09%-231.25%-293.48%-88.82%-117.70%
FCF Margin
-101.99%-161.65%-223.95%-219.57%-80.32%-147.22%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.651.725.7816.4710.5328.11